Evidence for ABL amplification in multiple myeloma and therapeutic implications

doi:10.21203/rs.3.rs-48781/v2

Download PDF

Research

Evidence for ABL amplification in multiple myeloma and therapeutic implications

https://doi.org/10.21203/rs.3.rs-48781/v2

This work is licensed under a CC BY 4.0 License

Journal Publication

published 15 Mar, 2022

Read the published version in Journal of Oncology →

Version 2

posted

You are reading this older preprint version

Read the latest preprint version →

Background: Cytogenetic abnormalities are considered initiating events in the pathogenesis of multiple myeloma (MM) and are assumed to be of clinical significance.

Methods: Fluorescence in situ hybridization (FISH) was used to analyze chromosomal architecture in 101 patients with MM. We evaluated overall patient survival and assessed cytotoxicity of imatinib against MM cells using a CCK8 assay.

Results: ABL gene amplification was detected in 67 patients (66.3%). However, ABL gene amplification was not associated with clinical features, cytogenetic abnormalities (c-Myc amplification, IGH rearrangement, RB1 deletion, p53 deletion, or 1q21 amplification), or overall survival. ABL amplification in MM cell lines (LP-1 and U266) was revealed by FISH. Furthermore, the ABL protein was easily detectable in MM cell lines and some tumor cells by western blotting. A CCK8 assay indicated limited cytotoxicity of imatinib against MM cells.

Conclusions: Our study firstly discussed ABL gene amplification was prevalent in MM cells, and we believe ABL gene would potentially be a useful target in the treatment of combination strategy for MM with ABL amplification in future.

Cancer Biology

Oncology

ABL amplification

Multiple myeloma

Chromosome

FISH

Multiple myeloma (MM) is one of the most common hematological tumors and is characterized by malignant proliferation of plasma cells. Despite encouraging therapeutic advances, the disease remains incurable because of complex genomic alterations, low sensitivity of MM cells to chemotherapy in the bone marrow microenvironment, and emergence of drug resistance [1]. Accumulating evidence suggests that at the time of diagnosis, genotypic changes can be detected in approximately 60% of patients by conventional chromosome analysis and in up to 90% of patients by fluorescence in situ hybridization (FISH). Some genetic abnormalities have been identified and include rearrangement of the 14q32 (IGH) locus/c-Myc/cyclin D1/FGFR3/cyclin D3, monoallelic deletions of chromosome 13, mutations of the K-Ras and N-Ras genes, and p53 monoallelic loss [2]. Using DNA microarrays, the gene expression profiles of malignant plasma cells from nine patients with MM and eight MM cell lines were compared with those of highly purified nonmalignant plasma cells from eight individuals following in vitro differentiation of peripheral blood B cells. Overall, 250 genes were significantly up-regulated and 159 were down-regulated in malignant plasma cells compared with normal cells. Some of these differentially expressed genes, including ABL, are over-expressed in MM cells and code for enzymes that could be targeted with drugs [3].

ABL is activated by chromosomal translocations in kinds of hematopoietic malignancies, particularly chronic myeloid leukemia (CML) characterized in almost all cases by the t (9;22) (q34; q11) translocation. In addition, ABL fusion proteins are inseparable from tyrosine kinase activity, so small-molecule inhibitors (e.g., imatinib, also known as STI571 or Gleevec) can achieve therapeutic outcomes by targeting kinase activity. ABL is localized both in the nucleus and the cytoplasm. DNA damage and genomic instability lead to the high expression of ABL in MM nucleus and the disruption of the ABL-YAP1-p73 axis damages most nuclear tumor suppressor functions. Low YAP1 levels prevent nuclear ABL-induced apoptosis following endogenous DNA damage, thus representing a new synthetic-lethal strategy to selectively target cancer cells [4, 5].

FISH is a versatile and expandable that can greatly facilitate research and diagnostics. Here, we used FISH to perform chromosomal profiling and undertake an analysis of ABL amplification in MM bone marrow samples and cell lines. The ABL gene was frequently amplified in MM cells, often by 3- or 4-fold. Compared with CML cells bearing the BCR-ABL fusion gene, imatinib monotherapy had limited anti-tumor effects on MM cells with ABL amplification as shown by cell proliferation assays. ABL has been identified as a selective target for synthetic-lethal strategies in MM [4]. Thus, information on ABL regulatory mechanisms is being mined to suggest potential therapeutic strategies against hematopoietic malignancies [6, 7], especially as part of combination therapies.

2.1 Patients

We screened the databases of the clinical cytogenetics laboratories at the Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University from June 2009 to July 2018. A total of 101 patients with MM, including 11 patients with relapsed MM, were enrolled based on the International Myeloma Working Group criteria. Baseline data included sex, age, M protein subtype in serum or urine, Durie-Salmon (DS) stage, serum levels of creatinine, albumin, β₂-microglobulin (β_2-MG), and lactate dehydrogenase (LDH), and bone marrow karyotype. Of the 101 patients, only 82 cases received at least one type chemotherapy regimen as following: vincristine + adriamycin/ doxorubicin + dexamethasone (42 cases), bortezomib + dexamethasone (36), lenalidomide + dexamethasone (11), lenalidomide + bortezomib + dexamethasone (4), ixazomib + dexamethasone (1), lenalidomide + ixazomib + dexamethasone (3), and thalidomide + dexamethasone (8). None of them had received autologous or allogeneic stem cell transplantation or immunotherapy. All patients provided written informed consent for use of their samples. The study was approved by the ethics committees of the Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University.

2.2 Cell lines, proteins and regents

K562, NCI-H929, LP-1, and U266 cell lines were obtained from the ATCC (Manassas, VA, USA). Cells were cultured in RPMI 1640 medium (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 10% (v/v) heat-inactivated fetal bovine serum (Gibco BRL, Gaithersburg, MD, USA) at 37°C under a humidified atmosphere containing 5% CO₂. Protein extracts from RPMI8226, NB4, U937, Kasumi-1, 293T, HCC1937, PC3, and OVCAR-3 cells were kind gifts from Professor Yingli Wu (Department of Pathophysiology, Key Laboratory of Cell Differentiation and Apoptosis, Chinese Ministry of Education Shanghai Jiao-Tong University School of Medicine). Imatinib (STI571) was purchased from Selleck Chemicals (Houston, TX, USA). A 1-mM stock solution was prepared in dimethyl sulfoxide and stored at -20°C.

2.3 Conventional karyotyping

Bone marrow cells from patients with MM were cultivated for 24 to 48 hours without mitogen stimulation and harvested for chromosomal examination using standard techniques. At least 20 metaphases with R-banding using Giemsa stain were examined. The International System for Human Cytogenetic Nomenclature (2009) was used to describe chromosomal abnormalities.

2.4 Fluorescence in situ hybridization

We used commercially available probes targeting c-Myc (8q24), D13S319/RB1/ (13q14), p53/1q21 (17p13.1/1q21), IGH (14q32), CSP17/CDKN2A (p16) (9p21) and BCR/ABL (22q11/9q34) (GP Medical, Beijing, China) to analyze 101 specimens by inter/metaphase FISH. Interphase signals were evaluated in 200 nuclei. Expression of two green and two orange signals was considered normal. Images were captured using a Nikon 80-A1 fluorescent microscope (eyepiece: NIKON Japan 10×; objective: NIKON Japan 100×; NIKON, Tokyo, Japan) and analyzed using image analysis software AI (Gene Company, Beijing, China). The color filters included SP100v2 DAPI c126877, 61000v2 D/F/R c126876, and FITC ex465-495 DM505 BA515-555. Images were captured using a camera from Bino Photo.

2.5 Single-nucleotide polymorphism array

DNA was extracted from bone marrow aspirates collected in tubes containing ethylenediaminetetraacetic acid. Genome-wide hybridization was performed using an Affymetrix 750k SNP microarray. The procedure was carried out strictly according to the Affymetrix standard operating procedure. The assay can detect copy number variation and loss of heterozygosity at genome scale. If all quality control standards were acceptable, data analysis was carried out using Affymetrix ChAs software. The analysis was carried out using normal control standards from the Affymetrix Normal Population Gene Database.

2.6 Cell proliferation assay

Cells were seeded in 96-well plates and incubated with various concentrations of drugs in triplicate for 48 hours. Cell proliferation was assayed using a Cell Counting Kit-8 (CCK8) (Dojindo Laboratories, Kumamoto, Japan) according to the manufacturer’s instructions. Each experiment was conducted in triplicate and experiments were repeated three times.

2.7 Western Blot

Cells were harvested, washed with PBS and lysed with lysis buffer (62.5 mM Tris-HCl, pH 6.8, 100 mM DTT, 2% SDS, 10% glycerol). Cell lysates were centrifuged at 20,000 g for 10 minutes at 4℃, and proteins in the supernatants were quantified. Protein extracts were equally loaded to 6% to 15% SDS–PAGE gels, electrophoresed, and transferred to nitrocellulose membrane. After blocking with 5% nonfat milk in PBS for 2 hours at room temperature, the membranes were incubated with antibodies against c-ABL was purchased from Santa Cruz Biotechnology (Santa Cruz, CA) overnight at 4℃ followed by horseradish peroxidase (HRP)-conjugated secondary antibodies for 1 hour at room temperature. Signals were detected using a chemiluminescence phototope-HRP kit (Millipore, Burlington, MA, USA) according to the manufacturer’s instructions. Blotting using a monoclonal antibody against of α-tubulin (Cell Signaling Technology, Danvers, MA, USA) was used as an internal control.

2.8 Statistical analysis

Depending on the distribution, continuous data were presented as medians (interquartile ranges) or as means ± standard deviations. Categorical data were presented as counts or proportions. Differences between groups were assessed using χ² tests or Fisher’s exact tests for categorical data and using nonparametric Wilcoxon rank-sum tests or Student’s t-tests for continuous data. Univariate and multivariate logistic regression analyses were used to assess the relationship between ABL amplification and normal ABL groups. Statistical analyses were performed using Empower (R) (www.empowerstats.com, X&Y Solutions, Boston, MA, USA) and R (http://www.R-project.org). Survival curves were constructed using the Kaplan-Meier method and compared using the log-rank (Mantel–Cox) test. A two-tailed value of P < 0.05 was considered statistically significant.

3.1 ABL amplification is frequent in patients with MM

A total of 101 patients with MM (including 11 patients with relapsed MM) were enrolled in the study. We assessed the cytogenetic characteristics of each patient’s bone marrow cells. Patient baseline demographic and clinical features are summarized in Table 1. Among the MM patients, 67 patients (66.3%) had cytogenetic abnormalities with ABL amplification identified by FISH. No significant differences were observed between patients with ABL amplification and those with normal ABL gene in terms of sex, age, M protein, DS stage, LDH, creatinine, albumin, β₂-MG, or karyotype. The frequencies of c-Myc amplification, IGH rearrangement, p53 deletion, and 1q21 amplification were higher in patients with ABL amplification than in those with normal ABL group. The frequency of D13S319/RB1 deletion was lower in patients with ABL amplification than in those with normal ABL gene (56.7% vs 64.8%). However, differences in cytogenetic abnormalities (Table 1) were not statistically significant (P > 0.05). In contrast, significant differences in karyotype were observed between the two groups. Hyperdiploidy, reflecting better prognosis [8] was more frequent in patients with ABL amplification (32.8%, 22/67) than in patients with normal ABL gene (5.9%, 2/34). Normal karyotypes were present in 65.7% (44/67) of patients with ABL amplification and 76.5% (26/34) of patients with normal ABL gene. Hypodiploidy, reflecting poor prognosis [9], was detected in 17.6% (6/34) of patients with normal ABL group and no patients with ABL amplification. Only one sample exhibited polyploidy; this sample showed ABL amplification, c-Myc amplification, IGH rearrangement, p53 deletion, and 1q21 amplification. Thus, ABL amplification was more frequent in MM cells with hyperdiploidy.

Because ABL is located on chromosome 9, which is frequently duplicated as a numerical chromosomal abnormality in MM, we further examined CDKN2A p16 (located at 9p21) to exclude the possibility of trisomy chromosome 9. And p16 amplification was inconsistent with ABL amplification (Figure 1A). Moreover, we tested several samples by SNP array after CD138⁺ cell sorting and found that samples with ABL amplification had normal chromosome 9. Figure 1B shows SNP array results for one patient who had ABL amplification but no increase on chromosome 9. Thus, we concluded that ABL amplification was not caused by chromosome 9 increase.

We further analyzed differences in overall survival (OS) between MM patients with ABL amplification and those with normal ABL gene. Seven patients were lost to follow-up (four patients with ABL amplification and three with normal ABL gene). The median survival of patients with ABL amplification and those with normal ABL gene were 25 months and 34 months, respectively. This difference was not statistically significant (P > 0.05) (Figure 2).
3.2 Chromosomal characteristics of MM cell lines

To further assess the performance of FISH probes targeting small genomic loci in MM cell lines, we assessed the human MM cell lines LP-1, U266, and NCI-H929 (characterized by hyperdiploidy with 61–69 chromosomes and a variety of structural abnormalities) and the CML cell line K562 (characterized by hyperdiploidy and multiple BCR-ABL fusion gene amplifications). The GLP IGH dual color breakpoint probe (located at 14q32), p53/1q21 probe (located at 17p13.1/1q21), D13S319/RB1 probe (located at 13q14), GLP c-Myc dual color breakpoint probe (located at 8q24), and GLP BCR-ABL dual color fusion probe (located at 22q11/9q34) were detected by FISH in MM cell lines. As shown in Table 2, we observed ABL amplification in LP-1 cells (three or four orange signals for the ABL gene) and U266 cells (four orange signals for the ABL gene). By contrast, NCI-H929 cells had normal ABL gene. Visualization of chromosomal territories using FISH chromosome-spotting probes revealed genes indicating poor prognosis in agreement with Hi-C measurements. In NCI-H929 cells, c-Myc, IGH, D13S319/RB1, and 1q21 appeared to have undergone triple amplification. In LP-1 cells, c-Myc was amplified 6-fold, 1q21 was amplified 8–10-fold, and IGH was rearranged. In U266 cells, c-Myc was amplified 4-fold, 1q21 was amplified 6-fold, and the deletion of variable region of IGH, p53, and D13S319/RB1. As shown in Figure 3A–C, c-Myc amplification, IGH rearrangement, p53 deletion, and 1q21 amplification were confirmed by metaphase or interphase FISH in MM cell lines. In addition, D13S319/RB1 showed different chromosomal abnormalities (amplification in NCI-H929 cells; normal in LP-1 cells; loss in U266 cells). In K562 cells, multiple BCR-ABL fusion gene amplifications were detected by FISH as a positive control (Figure 3D).

3.3 ABL protein expression in MM cell lines

ABL genes are found in all metazoans. ABL fusion genes can transform human fibroblasts in cultures, and enhanced ABL signaling may contribute to epithelial cell malignancies and to invasive growth of breast cancer cells [10-12]. We next examined ABL protein expression in both hematologic cancer cells and solid tumors. ABL was relatively easily detected in most cells (Figure 4). Expression of c-ABL could be identified in NCI-H929, LP-1, U266 and RPMI 8226 cells; none of these cells have BCR-ABL fusion proteins. As described above, FISH was used to analyze ABL amplification in the nuclei of MM cell lines. NCI-H929 cells did not show ABL amplification. Because c-ABL localizes both to the nucleus and the cytoplasm, ABL protein levels are not predictive of FISH performance.

3.4 Cytotoxicity of the ABL inhibitor imatinib against MM cells

The concentration of imatinib necessary to obtain 50% inhibition in MM cell proliferation (IC₅₀) was high (>10 μM ) (Figure 5) compared with the BCR-ABL fusion gene-expressing CML cell line K562 (0.5 μM) (data not shown), consistent with previous studies [13]. Imatinib targets BCR-ABL mainly in the cytoplasm via interaction close to the ATP binding site, and thus minimally affects ABL expression in the nucleus [14]. Therefore, ABL kinase inhibitors may restrict MM proliferation weakly compared with CML cells because of different underlying mechanisms of tumor cell development. However, imatinib may have synergistic effects in combination therapy regimens for MM.

MM is a genetically heterogeneous disease with diverse clinical outcomes. Increasingly, genetic abnormalities are being explored in MM research and diagnostics because of advances in DNA techniques. Copy number alterations, including whole chromosome and sub-chromosomal gains and losses, are common contributors to pathogenesis and have demonstrated prognostic impact in MM [15]. In addition, profiling using SNP arrays and next-generation sequencing have extensively and deeply characterized the genomic landscape of MM. FISH, a publicly available resource enabling versatile studies of genome architecture, is a powerful method to study chromosomal organization in single cells. FISH is reliable and provides comprehensive profiling of disease-related genetic aberrations, including deletions, amplifications, inversions, and fusion genes, with a short turn-around time. Thus, FISH could represent a valuable addition to the diagnostic methods currently used for genetic characterization of MM, especially for risk stratification in prognosis and in patients being treated with bortezomib.

The BCR-ABL fusion gene is involved in the Philadelphia chromosome of CML, but is rarely reported in myelomas. Previous studies have confirmed over-expression of ABL gene in malignant vs. normal plasma cells [3]. Here, we showed that ABL gene amplification was pervasive in MM patients and MM cell lines by FISH. In addition, ABL protein was easily detectable in MM and other tumor cell lines. ABL gene amplification was more common in MM cells with hyperdiploid karyotypes, which was often accompanied by complex genetic abnormalities, including c-Myc amplification, IGH rearrangement, p53 deletion, and 1q21 amplification. Consistent with previous research [13], our results suggest that tyrosine kinase inhibitors were less efficacious in ABL-amplified MM cells compared with BCR-ABL positive cells. Although the ABL kinase inhibitor imatinib had weak cytotoxicity against MM cells, it may be useful as a component of combination therapy regimens.

This is the first investigation of the role of ABL amplification in MM. We confirmed nuclear ABL geneamplification in MM patients. However, it is regrettable that we were unable to further purify cells using CD138 magnetic beads, which might have better validated chromosomal abnormalities. A future study will be based on CD138 expression immunophenotyping enrichment to assess genotypic differences. ABL expression is prevalent in MM cells in response to DNA damage, and thus we found no associations between ABL amplification and clinical manifestation or survival. MM is characterized by high degree of genetic heterogeneity, and almost all patients with MM have chromosomal abnormalities. Currently, there are only a few confirmed chromosomal abnormalities associated to prognostic risk stratification, and most of them are still being explored. ABL amplification was common in hyperdiploid patients (presenting with trisomy characteristics) and was often together with other chromosomal abnormalities, so that thousands of abnormal genes expression involved in a single patient. Therefore, we believe that ABL gene amplification is only a part of the complex chromosomal abnormality of MM and may play a comparative weak role in prognosis. This result remains to be confirmed in larger studies.

Most tumor cells have constitutive ABL activation. However, tyrosine kinase inhibitors have cytotoxic effects in only a few hematologic malignancies with BCR-ABL fusion genes including CML, myelodysplastic syndrome [16], and BCR-ABL-positive MM [17]. However, the combination of tyrosine kinase inhibitors with anti-interleukin-6 antibodies induced marked inhibition of myeloma cell proliferation at low concentrations [3]. In MM and in other hematologic and solid malignancies, genomic instability, centrosome amplification, and aneuploidy are associated with the overexpression of Aurora kinases, a family of serine/threonine kinases that play essential roles in mitosis [18]. Thus, combined inhibition of Aurora and ABL kinases resulted in cell death and tumor regression in MMs mediated by a NF-κB-inducing kinase-c-ABL-STAT3 signaling-centered feedback loop [6]. Conversely, Cai et al. indicated that activation of c-ABL kinase potentiated the anti-myeloma drug lenalidomide by promoting DDA1 recruitment to the CRL4 ubiquitin ligase. Furthermore, panobinostat (a histone deacetylase inhibitor) and dexamethasone enhance lenalidomide-induced substrate degradation and cytotoxicity by activating c-ABL, suggesting a mechanism underlying their synergistic effects with lenalidomide in treating MM [7]. In the past decade, three- or four-drug regimens have become increasingly popular for treatment of MM. ABL kinase inhibitors can also be applied in these regimens. ABL includes nuclear localization signals and a DNA binding domain that mediate its DNA damage-repair functions. Cytoplasmic ABL has binding capacity for actin and microtubules to enhance its cytoskeletal remodeling functions. Various types of posttranslational modifications can regulate the catalytic activity, subcellular localization, and stability of ABL, thus affecting cytoplasmic and nuclear ABL functions [19]. Therefore, the regulatory mechanisms of ABL needs to be explored to provide a basis for the clinical application of related drugs against hematopoietic malignancies.

Data Availability

The underlying data used to support our findings of this study are available from the corresponding author on request.

Conﬂicts of Interest

The authors declare no conflict of interest.

Ethical approval

The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The trial was conducted in accordance with the Declaration of Helsinki (as revised in 2013).

Funding: This work was supported by Wenzhou Municipal Science and Technology Bureau (CN) (Y20190538).

Acknowledgements

We thank the patients and Professor Yingli Wu (Department of Pathophysiology, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education Shanghai Jiao-Tong University School of Medicine) for kindly providing proteins.

Authors’ contributions

Conceptualization and design: Kang Yu and Qian Li. Development of methodology: He Huang, Wenjian Guo, Licai He and Qian Li. Acquisition of data: He Huang, Hongdou Lin, Ying Lin and Qian Li. Analysis and interpretation of data: He Huang, Shuping Zhou，Ronxin Yao and Qian Li. Writing and review of the manuscript: He Huang and Qian Li. Administrative, technical, or material support: He Huang, Wenjian Guo, Licai He and Qian Li. The authors read and approved the final manuscript.

[1] H. N. Abramson, “The Multiple Myeloma Drug Pipeline-2018: A Review of Small Molecules and Their Therapeutic Targets in sentence style,” Clin Lymphoma Myeloma Leuk title, vol.18, no.9, pp. 611-627, 2018.

[2] P. L. Bergsagel, W. M. Kuehl, “Chromosome translocations in multiple myeloma in sentence style,” Oncogene title, vol.20, no.40, pp. 5611-5622, 2001.

[3] J. De Vos, T. Thykjaer, K. Tarte, M. Ensslen, P. Raynaud, G. Requirand et al, “Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays in sentence style,” Oncogene title, vol.21, no.44, pp. 6848-6857, 2002.

[4] F. Cottini, T. Hideshima, C. Xu, M. Sattler, M. Dori, L. Agnelli et al, “Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers in sentence style,” Nat Med title, vol.20, no.6, pp. 599-606, 2014.

[5] D. K. Walters, X. Wu, R. C. Tschumper, B. K. Arendt, P. M. Huddleston, K. J. Henderson et al, “Evidence for ongoing DNA damage in multiple myeloma cells as revealed by constitutive phosphorylation of H2AX in sentence style,” Leukemia title, vol.25, no.8, pp. 1344-1353, 2011.

[6] L. Mazzera, M. Abeltino, G. Lombardi, A. M. Cantoni, R. Ria, M. Ricca et al, “Functional interplay between NF-kappaB-inducing kinase and c-Abl kinases limits response to Aurora inhibitors in multiple myeloma in sentence style,” Haematologica title, vol.104, no.12, pp. 2465-2481, 2019.

[7] S. Gao, C. Geng, T. Song, X. Lin, J. Liu, Z. Cai et al, “Activation of c-Abl Kinase Potentiates the Anti-myeloma Drug Lenalidomide by Promoting DDA1 Protein Recruitment to the CRL4 Ubiquitin Ligase in sentence style,” J Biol Chem title, vol.292, no.9, pp. 3683-3691, 2017.

[8] J. Mei, Y. Zhai, H. Li, F. Li, X. Zhou, P. Song et al, “Prognostic impact of hyperdiploidy in multiple myeloma patients with high-risk cytogenetics: a pilot study in China in sentence style,” J Cancer Res Clin Oncol title, vol.144, no.11, pp. 2263-2273, 2018.

[9] S. Van Wier, E. Braggio, A. Baker, G. Ahmann, J. Levy, J. D. Carpten et al, “Hypodiploid multiple myeloma is characterized by more aggressive molecular markers than non-hyperdiploid multiple myeloma in sentence style,” Haematologica title, vol.98, no.10, pp. 1586-1592, 2013.

[10] T. G. Lugo, O. N. Witte, “The BCR-ABL oncogene transforms Rat-1 cells and cooperates with v-myc in sentence style,” Mol Cell Biol title, vol.9, no.3, pp. 1263-1270, 1989.

[11] J. Lin, R. Arlinghaus, “Activated c-Abl tyrosine kinase in malignant solid tumors in sentence style,” Oncogene title, vol.27, no.32, pp. 4385-4391, 2008.

[12] D. Srinivasan, R. Plattner, “Activation of Abl tyrosine kinases promotes invasion of aggressive breast cancer cells in sentence style,” Cancer Res title, vol.66, no.11, pp. 5648-5655, 2006.

[13] A. Pandiella, X. Carvajal-Vergara, S. Tabera, G. Mateo, N. Gutierrez, J. F. San Miguel, “Imatinib mesylate (STI571) inhibits multiple myeloma cell proliferation and potentiates the effect of common antimyeloma agents in sentence style,” British journal of haematology title, vol.123, no.5, pp. 858-868, 2003.

[14] P. Vigneri, J. Y. Wang, “Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase in sentence style,” Nature medicine title, vol.7, no.2, pp. 228-234, 2001.

[15] S. Kosztolanyi, R. Kiss, L. Atanesyan, A. Gango, K. de Groot, M. Steenkamer et al, “High-Throughput Copy Number Profiling by Digital Multiplex Ligation-Dependent Probe Amplification in Multiple Myeloma in sentence style,” J Mol Diagn title, vol.20, no.6, pp. 777-788, 2018.

[16] S. Doi, Y. Tashiro, N. Yoshinaga, W. Kishimoto, T. Hamada, C. Ueda et al, “[BCR-ABL1-positive myelodysplastic syndrome with neutropenia and anemia treated successfully with imatinib mesylate] in sentence style,” Rinsho Ketsueki title, vol.61, no.5, pp. 455-461, 2020.

[17] K. Miki, N. Obara, K. Makishima, T. Sakamoto, M. Kusakabe, T. Kato et al, “An Unprecedented Case of p190 BCR-ABL Chronic Myeloid Leukemia Diagnosed during Treatment for Multiple Myeloma: A Case Report and Review of the Literature in sentence style,” Case Rep Hematol title, vol.2018, no., pp. 7863943, 2018.

[18] T. Otto, P. Sicinski, “Cell cycle proteins as promising targets in cancer therapy in sentence style,” Nature reviews Cancer title, vol.17, no.2, pp. 93-115, 2017.

[19] J. Colicelli, “ABL tyrosine kinases: evolution of function, regulation, and specificity in sentence style,” Sci Signal title, vol.3, no.139, pp. re6, 2010.

Table 1 Baseline characteristics of patients with multiple myeloma.

Patient characteristics

ABL amplification (n=67) No. (%)

Normal ABL gene (n=34) No. (%)

Gender

Male

Female

Age(years)

Median

M component

IgG

IgA

IgD

DS stage

III

Creatinine (μmol/L)

Albumin (g/L)

β₂-MG (mg/L)

3.5-5.5

LDH (U/L)

Karyotype

Hyperdiploidy

Hypodiploid

Polyploidy

Normal karyotype

Coexistent adverse cytogenetics

C-Myc amplification

IGH rearrangement

D13S319/RB1 deletion

p53 deletion

1q21 amplification

48（71.6）

19（28.4）

36（53.7）

31（46.3）

44（65.7）

20（29.9）

1（1.5）

2（3.0）

7（10.4）

4（6.0）

56（83.6）

55（82.1）

12（17.9）

5（7.5）

62（92.5）

19（28.4）

26（38.8）

22（32.8）

49（73.1）

18（26.9）

22（32.8）

1（1.50）

44（65.7）

31 (46.3)

45 (67.2)

38 (56.7)

5 (14.9)

34 (50.7)

20（58.8）

14（41.2）

21（61.8）

13（38.2）

18（52.9）

9（26.5）

3（8.8）

4（11.8）

1（2.9）

2（5.9）

31（91.2）

33（97.1）

1（2.9）

7（20.6）

27（79.4）

16（47.1）

9（26.5）

27（79.4）

7（20.6）

2（5.9）

6（17.6）

26（76.5）

10（29.4）

20 (58.8)

22 (64.7)

2 (5.9)

15 (44.1)

0.194

0.292

0.133

0.476

0.055

0.099

0.228

0.475

<0.001

0.103

0.408

0.528

0.768

0.440

Table 2 Genomic profiling of multiple myeloma cell lines by FISH.

Karyotype	NCI-H929	LP-1	U266	K562
BCR/ABL	2G2O	3G3O=70%/4G4O=30%	4G4O=25%	Multiple F
C-Myc	3F	6F	4F=27%
IGH	3F	2F6G2O	2F2O=21%,FO=79%
D13S319/RB1	3G3O	2G2O	2G2O=19%,GO=81%
p53/1q21	2G3O	3G8-10 O	2G6O=26%,G2O=74%

F: Fusion, G: Green, O: Orange, 2G2O: Normal

Download PDF

Journal Publication

published 15 Mar, 2022

Read the published version in Journal of Oncology →

Version 2

posted

You are reading this older preprint version

Read the latest preprint version →

Evidence for ABL amplification in multiple myeloma and therapeutic implications

Status:

Journal Publication

Version 2

Abstract

Figures

Introduction

Materials And Methods

Results

Discussion

Declarations

Reference

Tables

Status:

Journal Publication

Version 2